Attorney Docket: 2458-4042US3 Applicant: DENTON, et al. Filing Date: December 21, 2001

Serial No.: 10/019,243

Group Art Unit:

INFORMATION DISCLOSURE CITATION

U.S. PATENT DOCUMENTS

Examiner	Patent	Publication	<u> </u>	1	T	· · · · · · · · · · · · · · · · · · ·
Initial	Number	Date	Name	Class	Sub-Class	Filing Date
mes	5,966,711	10/12/1999	Adams	1	/	
1	6,043,040	03/28/2000	Acton		 	
	6,030,778	02/29/2000	Acton et al.	 	 /-	
	6,223,128 B1	4/24/2001	Allex et al.	 	/	
	5,121,320	6/9/1992	Aoki et al.	 	 /-	-
	6,222,559 B1	4/24/2001	Asano et al.	 	 	- · · -
	6,185,561 B1	2/6/2001	Balaban et al.		 	
	6,081,786	06/27/2000	Barry et al.	 	 /	
	6,188,988	02/13/2001	Barry et al.	 	1 /	
	5,874,256	02/23/1999	Bertina et al.	1 1	1	
	5,866,404	2/2/1999	Bradshaw et al.	1	1	
	6,020,126	2/1/2000	Carlsson et al.		1 /	
	-6,219,674	04/17/2001	Classen	1		
	5,773,220	06/30/2000	Dekosky et al.		1-1	
	5,811,239	09/22/1998	Frayne			
	5,912,120	06/15/1999	Goldstein et al.			
	5,891,633	04/06/1999	Gonzalez et al.			
	5,297,288	3/22/1994	Hemminger et al.			
	5,762,876	6/9/1998	Lincoln et al.	1		
	5,811,235	09/22/1998	Jeffreys		1	
	5,853,989	12/29/1998	Jeffreys et al.		ĺ	
	6,094,626	7/25/2000	Kephart et al.			
	5,361,351	11/1/1994	Lenkov et al.	1		
	5,953,727	9/14/1999	Maslyn et al.	1 X		
	6,189,013 B1	2/13/2001	Maslyn et al.	1 /		
	6,175,830 B1	1/16/2001	Maynard	1		
	5,648,482	07/15/1997	Meyer		N	
<u> </u>	4,706,192	11/10/1987	Nasu et al.			
	6,214,556 B1	4/10/2001	Olek et al.			
	5,561,754	10/1/1996	Oliver et al.			
	5,559,944	9/24/1996	Ono			
	5,834,183	11/10/1998	Orr et al.			
	5,876,933	03/02/1999	Perlin			
	5,632,041	5/20/1997	Peterson et al.			
	6,022,683	02/08/2000	Poirer			
	5,862,304	1/19/1999	Ravdin et al.	1		
	6,178,382	01/23/2001	Roederer et al.	1/		
	6,141,657	10/31/2000	Rothberg et al.	1/		
	5,972,614	10/26/1999	Ruano et al.	1/	\\	
	5,970,500	10/19/1999	Sabatini et al.	V		
	5,966,712	10/12/1999	Sabatini et al.	1	\	ذــ

			ı	•
Examiner	Mprianne ? allen	Date Considered		
EXAMINER:	Initial if reference considered, whether or not citation is in confor	mance with MPEP §609.		
	Draw line through citation if not in conformance and not consider	ed.		
	Include copy of this form with next communication to Applicant.			

Attorney Docket:	Serial No.:	
2458-4042US3	10/019,243	
Applicant:		
DENTON, et al.		
Filing Date:	Group Art Unit:	
December 21, 2001	Group Art Unit:	

mek	5,972,604	10/26/1999	Santamaria et al		7
1	5,858,659	01/12/1999	Sapolsky et al.		
	5,187,775	2/16/1993	Schroeder et al.		/
	5,867,402	2/2/1999	Schneider et al.		
	6,023,659	2/8/2000	Seilhamer et al.		
	5,096,557	03/17/1992	Simons		7
	5,192,659	03/09/1993	Simons		
	5,612,179	03/18/1997	Simons		
	5,789,568	08/04/1998	Simons		
	5,851,762	12/22/1998	Simons		
	5,724,253	3/3/1998	Skovira		
	5,834,189	11/10/1998	Stevens et al.		
	5,618,672	4/8/1997	Stodola et al.	7	
7	5,885,776	03/23/1999	Stone et al.	7	
V	5,502,773	3/26/1996	Tibbetts et al.		

建品分量	學學不是學生學	FOR	EIGN PATENT DOCUMENTS		No. of the last of	海鸭 "鲁" 多说:
Examiner	भू प्रतिष् । इति स्वीत् प्रदेशीय से	Publication		. *	* 10 X13 E 134	and the state of the state of
Initial	Patent Number	Date	Country	Class	Sub-Class/	Translation
mek	WO 87/02802	5/7/1987	PCT	Class	Jub-Class/	☐ Yes ☐ No
mer	WO 91/05302	4/18/1991	PCT			☐ Yes ☐ No
	WO 92/01066	1/23/1992	PCT		/	☐ Yes ☐ No
 	WO 95/17524	6/29/1995	PCT	\	//	☐ Yes ☐ No
	WO 95/10805	4/20/1995	PCT	\	/	☐ Yes ☐ No
	WO 97/40462	10/30/1997	PCT	\	-/	☐ Yes ☐ No
-	WO 99/05323	02/04/1999	PCT			☐ Yes ☐ No
	WO 99/05324	02/04/1999	PCT	\ 	/	☐ Yes ☐ No
	WO 99/11822	3/11/1999	PCT	\	/	☐ Yes ☐ No
	WO 99/54500	10/28/1999	PCT	\ /		☐ Yes ☐ No
	WO 99/57308	10/20/1999		\/		☐ Yes ☐ No
	WO 99/64626	12/16/1999	PCT	X		☐ Yes ☐ No
	-WO 99/64627 ·	12/16/1999	PCT	/\		☐ Yes ☐ No
	WO 00/33161	06/08/2000	PCT	/		☐ Yes ☐ No
	WO 00/50639A2			/ - \		
	(cd format)		PCT	/ '	\	☐ Yes ☐ No
	WO 00/50639A3			/	\	
1 ,,:	(cd format)		PCT	/		Yes No
	WO 01/91026	11/29/2001	PCT /	<i></i>		Yes No
	/WO 02/064617	08/22/2002	PCT /		1	Yes No
	EP 0245466B1.	5/25/1994	EP /			☐ Yes ☐ No
	EP 0336560A2	10/11/1989	EP /			Yes No
	L-EP 0336560A3	10/11/1989	EP /		7	Yes No
	EP 0336560B1 ·	11/30/1994	EP (\	Yes No
	EP 0404682A2	12/27/1990	EP		\	Yes • No
	EP 0404682B1	12/27/1990	EP			Yes No
	y ₁ == 0.1.00=21			<u> </u>		<u> </u>

Examiner	Marianne P. allen	Date Considered 3/18/05
EXAMINER:	Initial if reference considered, whether or not citation is in conform	ance with MPEP §609.
	Draw line through citation if not in conformance and not considered	j.
	Include copy of this form with next communication to Applicant.	

		1 ago 5 OI
Attorney Docket:	Serial No.:	•
2458-4042US3	10/019,243	
Applicant:		
DENTON, et al.		
Filing Date:	Group Art Unit:	
December 21, 2001	TBA 1631	

mea	EP 0408188A2	1/16/1991	EP			☐ Yes ☐ No
	EP 0408188A3 ./	, 1/16/1991	EP			Yes No
•	EP 0408188B1 V	1/16/1991	EP			Yes No
	EP 0449494A2 \	10/2/1991	EP ·			Yes No
•	EP 0449494A3 🗸	10/2/1991	EP			Yes No
	EP 0449494B1	8/25/1999	EP			☐ Yes ☐ No
	EP 0474944A2 :/	3/18/1992	. EP			Yes No
	EP 0474944B1 V	7/16/1997	EP	/		Yes No
	EP 0481286A2 ,	4/22/1992	EP	/		Yes No
	EP 0481286B1 📐	4/9/1997	EP			☐ Yes ☐ No
•		5/15/1996	EP			☐ Yes ☐ No
	EP 0612846A1	8/31/1994	EP	/		Yes No
•	EP 0612846B1 V	8/16/2000	EP	7		☐ Yes ☐ No
	EP 0673523B1	2/10/1999	EP /		7	☐ Yes ☐ No
· V ·	EP 0812922A2 ·	12/17/1997	EP (,	☐ Yes ☐ No

de extension	OTHER DOCUMENTS (Including Author, Title, Date; Pertinent Papers, etc.).
MA	Beaudet, Arthur L., "1998 ASHG Presidential Address - Making Genomic Medicine a Reality", American Journal of Human Genetics, Vol. 64, pp. 1-13, 1999.
	Carter et al., "Genetic Control of Drug-Induced Recovery from Murine Visceral Leishmaniasis", J. Pharm. Pharmacol. 1994, 45:795-798
	Cashman, Siobhan M. et al., "The Irish Cystic Fibrosis Database", Journal of Medical Genetics, Vol. 32, pp. 972- 975, July 1995.
	Chakraborty, R. "A Class of Population Genetic Questions Formulated as the Generalized Occupancy Problem", Genetics, July 1993, 134:953-958
	Chiano et al. "Fine Genetic Mapping Using Haplotype Analysis and the Missing Data Problem", Ann. Hum. Genet., 1998, 62:55-60.
	Clark, Andrew G. et al., "Haplotype Structure and Population Genetic Inferences From Nucleotide-Sequence Variation in Human Lipoprotein Lipase", American Journal of Human Genetics, Vol. 63, pp. 595-612, 1998.
	Clark, Andrew G., "Inference of Haplotypes from PCR-amplified Samples of Diploid Populations", Mol. Biol. Evol., 7(2):111-122, 1990
	Cooper, Gillian et al., "Network Analysis of Human Y Microsatellite Haplotypes", Human Molecular Genetics, Vol. 5, No. 11, pp. 1759-1766, 1996.
	Dempster et al., "Maximum Likelihood from Incomplete Data via the EM Algorithm", J. Statistical Society, Vol. 39, No. 1, pp.1-38, 1977
	Drefus et al. "Etude des Reactions Croisees des Antigenes HLA A et B Chez 63 Patients Atteints de Polyarthrite Rhumatoide", Revue du Rhumatisme, 1984, 51(4), 197-202
	Drysdale, "Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness", 2000, Proc. Natl. Acad. Sci. 97(19):10483-8
-	Excoffier et al., "Incorporating Genotypes of Relatives into a Test of Linkage Disequilibrium", Am. J. Hum. Genet., 62:171-180, 1998
7 ,	Excoffier et al. "Maximum-Likelihood Estimation of Molecular Haplotype Frequencies in a Diploid Populations", Mol. Biol. Evol., 1995, 12(5):921-927.
V	Fisher, Lloyd D. et al., "Biostatistics: A Methodology for the Health Sciences", pp. 345-495, 692-762, John Wiley & Sons, Inc.

Examiner	Moriano Ralle	Date Considered 3/18/05
EXAMINER:	Initial if reference considered, whether or not citation is in conform Draw line through citation if not in conformance and not considere Include copy of this form with next communication to Applicant.	
L	mented copy of and form mannext continuation to reppireum.	

		I ago 7 OI (
Attorney Docket:	Serial No.:	
2458-4042US3	10/019,243	
Applicant:		•
DENTON, et al.		
Filing Date:	Group Art Unit:	
December 21, 2001	TBA /63/	

	•	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.)
m	of.	Gene et al., "Haplotype Frequencies of Eight Y-chromosome STR loci in Barcelona (North-East Spain)", International Journal of Legal Medicine, Vol. 112, pp. 403-405, 1999.
	•	Hartl, Daniel L. et al., "Genetic and Phenotypic Variation", Principles of Population Genetics, pp. 37-109, Singuer Associates, Inc., 3 ed.
	•	Hawley et al., "HAPLO: A Program Using the EM Algorithm to Estimate the Frequencies of Multi-site Haplotypes", J. of Heredity, 86(5), pp. 409-411, 1995
	•	Hill et al., "Human Genetic Variation and Its Impact on Public Health and Medicine", pp.62-74
		Hill, "Tests for Association of Gene Frequencies at Several LOCI in Random Mating Diploid Populations", Biometrics, 31, 881-888, 1975
	•	Hoang, Liem et al., "PAH Mutation Analysis Consortium Database: A Database for Disease-Producing and Other Allelic Variation at the Human PAH Locus", Nucleic Acids Research, Vol. 24, No. 1, pp. 127-131, 1996.
	•	Jackson et al., "Pharmacokinetic-Pharmacogenetic Modelling in the Detection of Polymorphisms in Xenobiotic Metabolism", 1990, Ann. Occup. Hyg. 34(6):653-662
	•	Judosn et al., "The Predictive Power of Haplotypes in Clinical Response", 2000, pp.1-12
	8	Judson, Richard, "Genetic Algorithms and Their Use in Chemistry", Reviews in Computational Chemistry, Vol. 10, pp. 1-66, 1997
	•	Kalow et al., "The Science of Pharmacological Variability: An essay", Clin. Pharma. & Therapeutics, Vol. 66, No. 5, pp.445-447, 1999
	• ,	Kardia et al., "An Evolutionary Perspective on the Genetic Architecture of Susceptibility to Cardiovascular Disease", pp. 231-245
	•	Kleyn, Patrick W. et al., "Genetic Variation as a Guide to Drug Development", Science, Vol. 281, pp. 1820-1821, September 18, 1998.
	•	Kwok et al., "Single Nucleotide Polymorphism Libraries: Why and How are We Building Them?", Mol. Med. Today, 1999, Vol. 5, pp. 538-543
,		Layton et al., "The Therapeutic Response to D-Penicillamine in Rheumatoid Arthritis: Influence of Glutathione S-transferase Polymorphisms", Rheumatology, 1999, 38:43-47
		Long et al., "An E-M Algorithm and Testing Strategy for Multiple-Locus Haplotypes", Am. J. Hum. Genet., 56:799-810, 1995
		MacLean et al., "Estimation of Myriad Haplotype Frequencies", Genetic Epidemiology, 2:263-272, 1985
		Magon, "Pharmacogenetic interactions in G6PD deficiency and development of an in vitro test to predict a drug's hemolytic potential", 1981, Prog. Clin. Biol. Res., 55:709-24
		Matise, T.C., "Genome Scanning for Complex Disease Genes Using the Transmission / Disequilibrium Test and Haplotype-based Haplotype Relative Risk", Genetic Epidemiology, Vol. 12, pp. 641-645, 1995.
		Meyer, Urs A., "Medically Relevant Genetic Variation of Drug Effects", pp. 41-49
		Michalatos-Beloin et al. "Molecular Haplotyping of Genetic Markers 10 kb Apart by Allele-Specific Long Range PCR", Nucleic Acids Research, 1996, 24(23):4841-4843.
		Mori, Motomi et al., "Computer Program to Predict Likelihood of Finding an HLA-Matched Donor: Methodology, Validation, and Application", Biology of Blood and Marrow Transplantation, Vol 2, pp. 134-144, October 1996.
		Mori, Motomi et al., "HLA Gene and Haplotype Frequencies in the North American Population", Transplantation,. Vol. 64, No. 7, pp. 1017-1027, October 15, 1997.
		Neuman et al. "A Bit about Haplotypes: Using Binary Digits to Code Tightly Linked Loci", Hum. Hered., 1994 44:241-247
V		Niu et al, "Bayesian Haplotype Inference for Multiple Linked Single-Nucleotide Polymorphisms", Am. J. Hum Genet., 2002, 70:157-169

Examiner	Marianne allen	Date Considered	3/18/05	
EXAMINER:	Initial if reference considered, whether or not citation is in confor-	mance with MPEP §609.		
	Draw line through citation if not in conformance and not consider	ed.		
	Include copy of this form with next communication to Applicant.			

		1 450 2 01 (
Attorney Docket:	Serial No.:	
2458-4042US3	10/019,243	
Applicant:		
DENTON, et al.		
Filing Date:	Group Art Unit:	
December 21, 2001	TBA: 1631	

mes	Olsen et al., "Design and Sample-Size Considerations in the Detection of Linkage Disequilibrium with a Disease Locus", Am. J. Hum. Genet. 1994, 55:574-580
,	Perlin, Mark et al., "Toward Fully Automated Genotyping: Allele Assignment, Pedigree Construction, Phase
- -	Determination, and Recombination Detection in Duchenne Muscular Dystrophy", American Journal of Human
	Genetics, Vol. 55, pp. 777-787, June 1994.
	Press, William H. et al, "Numerical Recipes in C: The Art of Scientific Computing", pp. 394-455, Cambridge
	University Press, 2 ed.
	Rich, Elaine et al., "Artificial Intelligence", pp. 514-519, McGraw-Hill, Inc., 2 ed.
	Ruano et al. "Haplotype of Multiple Polymorphisms Resolved by Enzymatic Amplification of Single DNA Molecu
	August 1990, Proc. Natl. Acad. Sci., Vol. 87, pp. 6296-6300
	R & D Directions Staff, "Beyond Genomics", R & D Directions, April 1999 pp. 40-44
1 1	Slatkin et al., "Testing for Linkage Disequilibrium in Genotypic Data Using the Expectation-Maximization
	Algorithm", Heredity, 76:377-383, 1996
	Staessen et al., "M235T Angiotensinogen Gene Polymorphism And Cardiovascular Renal Risk", J. Hypertension
	January 1999, 17(1):9-17.
	J.C. Stephens et al., "Haplotype Variation and Linkage Disequilibrium in 313 Human Genes", Science; 2001
	Stephens, J. Claiborne, "Single-nucleotide Polymorphisms, Haplotypes, and Their Relevance to Pharmacogenetic
4	Molecular Diagnosis, Vol. 4, No. 4, pp. 309-317, December 1999.
	Stephens et al., "A New Statistical Method for Haplotype Reconstruction from Population Data", Am. J. Hum.
	Genet., 2001, 68:978-989
	Thayer, Ann M., "Bioinformatics for the Masses", C&EN, 19-32, 2000
	Tishkoff S. A. et al., "The Accuracy of Statistical Methods for Estimation of Haplotype Frequencies: An Example from the CD4 Locus", American Journal of Human Genetics, Vol 67, pp. 518-522, August 2000.
+	Appleby, "Pharmaceutical Labs Exploring Drugs Tailored to Ethnicity, DNA", January 24, 1999, Las Vegas Rev
	- Journal, Section A, p. 26A.
+	Birt, "Drugs Industry Predicted to Be 'Microsoft' For the New Millenium", June 1, 1998, Birmingham Post, pg.
-	"Bursting with Innovation", December 1997, Med Ad News,
1	Craig, "Answers for the Toughest Challenges", April 19, 1999; Forbes, Supplement; Special Advertising Section
	Biotechnology, page 2.
	Debate, "California Spotlight: Incyte plans to conquer DNA mapping within year; Genetics: Part of the plan is t
	purchase British firm Hexagen for \$41 million", August 23, 1998, The Orange County Register, pg. K01.
	Furuta, "Race to Unlock Genetic Secrets Heats Up in Japan's Laboratories: Analysis of Genes Could Help Crea
	Tailor-Made Medicines", November 16, 1998, The Nikkei Weekly, pg. 1
	"Genaissance Raises \$10 Million in Private Placement; Accelerates Development of Personalized Medicines Thr
	Pharmacogenomics", August 27, 1998; PR Newswire, Financial News Section
	MacGregor, "Delay is Half The Cure: Nova's Merger With U.S. Firm Steps Up Research Aimed at Postponing
	Alzheimer's Until It No Longer Matters", March 10, 1999, The Gazette (Montreal), Section D1.
	"Mix/Match Analysis of Gene Diversity in Ethnic Cross-Section Aims at Personalized Medicine", 2001, Biowor
	Today, p. 5
	Regalado, "Inventing the Pharmacogenomics Business, Part I", September 1997, In Vivo the Business & Medic
	Report, p. 52.
	Sadee, Wolfgang, "Using Genetic Information to Optimize Drug Therapy", Medscape Pharmacotherapy, 2000

Examiner	Mariane P. alle	Date Considered	3/18/05
EXAMINER:	Initial if reference considered, whether or not citation is in conform	ance with MPEP §609.	
	Draw line through citation if not in conformance and not considered	1 .	
	Include copy of this form with next communication to Applicant.		

Page 6 of 6

FORM PTO-1449 INFORMATION DISCLOSURE CITATION

Attorney Docket:	Serial No.:	
2458-4042US3	10/019,243	
Applicant:		
DENTON, et al.		
Filing Date:	Group Art Unit:	
December 21, 2001	TBA-/63/	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, etc.)
mpt	The Genesis Group, "Will Pharmocogenomics Create a \$2 Billion Market?", July 1998, Genesis Report, 8(1); pg 26; 1061-2289
/	Genesis Group, "Will Pharmocogenomics Create a \$2 Billion Market?", July 1998, Genesis Report, 8(1); pg 26; 1-2289 ligen Acquires Berlin-Based Infogen and Phenotype Database", 2000, Worldwide Biotech triagenics, Inc. Acquires Exclusive Rights To Leading Pharmacogenomic Technologies for Neurological orders", February 8, 1999, Canada Newswire uhara, "Ethnic factors in evaluation of drug efficacy and safety", August 1994, Nippon Yakurigaku Zasshi, (2): 67-78 (English Abstract)
	"Variagenics, Inc. Acquires Exclusive Rights To Leading Pharmacogenomic Technologies for Neurological Disorders", February 8, 1999, Canada Newswire
V	Yasuhara, "Ethnic factors in evaluation of drug efficacy and safety", August 1994, Nippon Yakurigaku Zasshi, 102(2): 67-78 (English Abstract)
	Text of April 17, 2001 press release re: Classen patent No. 6,219,674
<u> </u>	

	Marianne Raller	Date Considered	3/18/05
EXAMINER:	Initial if reference considered, whether or not citation is in conform	ance with MPEP §609.	
	Draw line through citation if not in conformance and not considered	i .	
	Include copy of this form with next communication to Applicant.		



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18 Stylesheet Version v18.0

Title of Invention

Methods for Obtaining and Using Haplotype Data

Application Number:

10/019243

Confirmation Number:

3139

First Named Applicant: Richard Judson
Attorney Docket Number: MWH-0032US3

Search string:

(6537759 or 6664062).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
mes	1	6537759	2003-03-25	Stanton, Jr.	B1		
y	2	6664062	2003-12-16	Stanton, Jr.	B1		

Signature

Examiner Name	Date
Marianne P. allen	3/18/05

NO.297

P. B. JUL 27 2004

FORM PTO-1449
INFORMATION DISCLOSURE CITATION

Attorney Docket: 2458-4042US3	Serial No.: 10/019,243
Applicant DENTON, et al.	
Filing Date: December 21, 2001	Group Art Unit:

5,972,604	10/26/1999	Santamaria et al				
5,858,659	01/12/1999	Sapolsky et al.				
5,187,775	2/16/1993	Schroeder et al.			/	
5,867,402	2/2/1999	Schneider et al.		5	X	
6,023,659	2/8/2000	Seilhamor et al.		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
5,096,557	03/17/1992	Simons	A:	1 7/		
5,192,659	03/09/1993	Simons	` ,)/(
5,612,179	03/18/1997	Simons	1.77	103		
5,789,568	08/04/1998	Simons		N° /		
5,851,762	12/22/1998\	Simons	A. P. 10	1/		
5,724,253	3/3/1998	Skovira	NP V	7		
5,834,189	11/10/1998	Stevens ct al.		/	T .	
5,618,672	4/8/1997	Stodola et al.		1		
5,885,776	03/23/1999	Stone et al.				
5,502,773	3/26/1996	Tibbetts et al.				

Examiner	A THE PARTY OF THE	Publication				
Initial	Patent Number	Date	Country	Class	Sub-Class	Translation
	WO 87/02802	5/7/1987	PCT /			Yes No
	WO 91/05302	4/18/1991	PCT			☐ Yes ☐ No
	WO 92/01066	1/23/1992	PCT			Yes No
	WO 95/17524	6/29/1995	PCT			☐ Yes ☐ No
1	WO 95/10805	4/20/1995	PCT			Yes No
	WO 97/40462	10/30/1997	PCT /			☐ Yes ☐ No
•	WO 99/05323	02/04/1999	PCT /			☐ Yœ☐ No
	WO 99/05324	02/04/1999	PCT/			Yes No
	WO 99/11822	3/11/1999	POT			☐ Yes ☐ No
	WO 99/54500	10/28/1999	PCT			☐ Yes ☐ No
	WO 99/57308					☐ Yes ☐ No
	WO 99/64626	12/16/1999 /	PCT			Yes No
	PWO 99/64687	12/16/1999 /	PCT			☐ Yes ☐ No
	WO 00/33161	95/08/2000	PCT			☐ Yes ☐ No
7	WO 00/50639A2		PCT	1		Yes No
	(ed format)		\			
	WO 00/50639A3	//	PCT	Λ		Yes No
	(cd format)			1		
	WO 01/91026	11/29/2001	PCT			You No
	WO 02 7064617	08/22/2002	PCT	 \ 		☐ Yœ☐ No
	BP 0245466B1	/5/25/1994	EP	1		Yes No
	EP 0336560A2. /	10/11/1989	BP	 	-	Yes No
	EP 0336560A3/	10/11/1989	EP	 \-	ļ	
	BP 0336560B1	11/30/1994	EP	 	ļ	Yes No
	EP 0404682A2	12/27/1990	EP	·		Yes No
	BP 0404682B1	12/27/1990	EP	<u> </u>		LIESLING
Examiner		-	Date Considered		$\overline{}$	
EXAMINIE: Initial if reference considered, whether or not citation is in combinishes with MPEP 9009. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						

776315 v1

PTO/SE/08b (08-08)
Approved for use through 06/30/2008. OMB 0851-0091
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/019,243	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Fling Date	12/21/2001	
				First Named Inventor	Richard Judson	
				Art Unit .	2857 /63/	
				Examiner Name	Allen	
Sheet	1	of	1	Attorney Docket Number	2458-4042US3	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(e), volume-issue number(e), publisher, city and/or country where published.	7²			
MPA	AA	C WALL DISCORDED FOR AL SI existing Democrates Medal for Applying Detended Handstone				
:						
		·				
44						
	 		_			

Examiner Signature	marianne.	e aller	Date Considered	3/18/05

*EXAMINER: Initial if reference considered, whether or not clistion is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to piace a check mark here if English language Translation is attached.

This collection of information is required by 97 CFR 1.97 end 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 128 and 97 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and examiting the completed application form to the USPTO. Time will sury depending upon the inclindual asset. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief information Officer, U.S. Petent and Tredemark Office, U.S. Department of Commerce, P.C. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, oall 1-800-PTO-9199 and select option 2.